Published online May 26, 2017. doi: 10.4330/wjc.v9.i5.457
Peer-review started: October 23, 2016
First decision: December 1, 2016
Revised: March 13, 2017
Accepted: April 6, 2017
Article in press: April 10, 2017
Published online: May 26, 2017
Processing time: 214 Days and 19.2 Hours
To investigate feasibility of combined assessment of biochemical and electrophysiological myocardial impairment markers risk-stratifying patients with chronic heart failure (CHF).
Serum levels of heart-type fatty acid binding protein (H-FABP) as a marker of ongoing myocardial damage and QRS duration on electrocardiogram were measured at admission in 322 consecutive patients with CHF. A prolonged QRS duration was defined as 120 ms or longer. The cut-off value for H-FABP level (4.5 ng/mL) was determined from a previous study. Patients were prospectively followed during a median follow up period of 534 d. The primary endpoint was cardiac deaths and rehospitalization for worsening CHF.
There were 117 primary events, including 27 cardiac deaths and 90 rehospitalizations. Patients were stratified into four groups according to H-FABP level and QRS duration (≥ 120 ms). Multivariate analysis demonstrated that high H-FABP levels [hazard ratio (HR) = 1.745, P = 0.021] and QRS prolongation (HR 1.612, P = 0.0258) were independent predictors of cardiac events. Kaplan-Meier analysis demonstrated that the combination of high H-FABP levels and QRS prolongation could be used to reliably stratify patients at high risk for cardiac events (log rank test P < 0.0001).
Combined assessment of myocardial damage and electrical disturbance can be used to risk-stratify patients with CHF.
Core tip: This was a prospective single center study with 322 consecutive patients with chronic heart failure (CHF) seeking to evaluate the feasibility of combined assessment of biochemical and electrophysiological markers of myocardial impairment for risk-stratifying patients with CHF. QRS prolongation and high heart-type fatty acid binding protein levels are independently associated with cardiac events in patients with CHF.